Annexon, Inc. (NASDAQ:ANNX) Holdings Raised by AQR Capital Management LLC

AQR Capital Management LLC lifted its position in Annexon, Inc. (NASDAQ:ANNX) by 2,356.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 279,463 shares of the company’s stock after purchasing an additional 268,085 shares during the quarter. AQR Capital Management LLC owned 0.30% of Annexon worth $1,369,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Ameritas Investment Partners Inc. raised its holdings in shares of Annexon by 78.2% in the first quarter. Ameritas Investment Partners Inc. now owns 6,718 shares of the company’s stock valued at $48,000 after purchasing an additional 2,949 shares during the last quarter. Sandia Investment Management LP bought a new position in shares of Annexon in the 2nd quarter worth about $49,000. Victory Capital Management Inc. acquired a new stake in Annexon in the second quarter worth $51,000. Principal Financial Group Inc. bought a new position in shares of Annexon in the 2nd quarter worth $56,000. Finally, Comerica Bank bought a new position in shares of Annexon in the first quarter valued at approximately $72,000.

Annexon Price Performance

Shares of NASDAQ:ANNX opened at $7.02 on Friday. Annexon, Inc. has a 1 year low of $1.57 and a 1 year high of $8.40. The stock’s fifty day moving average price is $6.14 and its 200-day moving average price is $5.65. The company has a market cap of $648.74 million, a P/E ratio of -4.78 and a beta of 1.28.

Annexon (NASDAQ:ANNX) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.23) EPS for the quarter, hitting analysts’ consensus estimates of ($0.23). On average, sell-side analysts anticipate that Annexon, Inc. will post -0.97 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on ANNX shares. Needham & Company LLC restated a “buy” rating and set a $16.00 price target on shares of Annexon in a research note on Tuesday, August 13th. Cantor Fitzgerald restated an “overweight” rating on shares of Annexon in a report on Monday, September 9th. Finally, HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of Annexon in a report on Tuesday, August 13th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Annexon presently has a consensus rating of “Buy” and an average target price of $15.80.

Insiders Place Their Bets

In other news, EVP Ted Yednock sold 4,500 shares of the firm’s stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $7.10, for a total value of $31,950.00. Following the transaction, the executive vice president now directly owns 71,365 shares in the company, valued at $506,691.50. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. In the last quarter, insiders sold 17,388 shares of company stock valued at $107,072. Company insiders own 12.67% of the company’s stock.

Annexon Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.